TRxADE HEALTH, Inc. (NASDAQ:MEDS – Get Rating) – Equities research analysts at  Taglich Brothers lifted their Q1 2023 earnings estimates for shares of TRxADE HEALTH  in a report released on  Wednesday, April 12th. Taglich Brothers analyst H. Halpern now anticipates that the company will post earnings per share of ($0.02) for the quarter, up from their prior estimate of ($0.05). The consensus estimate for TRxADE HEALTH’s current full-year earnings is ($0.03) per share. Taglich Brothers also issued estimates for TRxADE HEALTH’s Q2 2023 earnings at ($0.01) EPS, Q3 2023 earnings at $0.00 EPS, Q4 2023 earnings at ($0.01) EPS and FY2023 earnings at ($0.03) EPS.

Separately, Maxim Group cut their target price on shares of TRxADE HEALTH from $2.50 to $1.75 and set a “buy” rating on the stock in a research report on Tuesday, March 28th.

NASDAQ:MEDS opened at $0.33 on Monday. The firm’s 50 day simple moving average is $0.35 and its 200 day simple moving average is $0.53. The company has a debt-to-equity ratio of 0.97, a current ratio of 0.97 and a quick ratio of 0.92. TRxADE HEALTH has a one year low of $0.25 and a one year high of $2.08. The company has a market cap of $3.34 million, a PE ratio of -0.80 and a beta of 1.28.

A hedge fund recently bought a new stake in TRxADE HEALTH stock. Armistice Capital LLC bought a new position in shares of  TRxADE HEALTH, Inc. (NASDAQ:MEDS – Get Rating) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 514,998 shares of the company’s stock, valued at approximately $207,000. Armistice Capital LLC owned 5.53% of TRxADE HEALTH at the end of the most recent reporting period. Hedge funds and other institutional investors own  7.18% of the company’s stock.

TRxADE HEALTH, Inc provides an online platform for pharmaceutical purchasers. It owns and operates a business-to-business web-based marketplace focused on the United States pharmaceutical industry. The firm operates a web-based market platform that enables trade among healthcare buyers and sellers of pharmaceuticals, accessories, and services.

Receive News & Ratings for TRxADE HEALTH Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRxADE HEALTH and related companies with MarketBeat.com's FREE daily email newsletter.